Riskpilot← Back to searchSign inGet full accessPharmaRelations ApS
APSActiveCVR 38215663Hummeltoftevej 49Activities of employment placement agencies · NACE 7810Est. 201624 employeeswww.pharmarelations.dk
Revenue 2024
DKK 22,4M
-4% vs 2023
EBITDA margin
1.6%
-66% vs 2023
Equity ratio
55.8%
Financial strength
Net profit 2024
DKK 254K
-64% vs 2023
| Revenue | DKK 22,4M | -4% |
| EBITDA | DKK 348K | -66% |
| Net profit | DKK 254K | -64% |
| Total assets | DKK 11,8M | +18% |
| Equity | DKK 6,6M | +4% |
| Employees | 24 | — |
Legal name
PharmaRelations ApS
CVR number
38215663
Legal form
Anpartsselskab
NACE code
7810 · Activities of employment placement agencies
Founded
22. november 2016
Share capital
DKK 50.000
Employees
24 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller en direktør.
Company purpose
Selskabets formål er at drive konulentvirksomhed (Talent Services) inden for Life Science samt hermed beslægtet virksomhed.
Address
Hummeltoftevej 49
Email
finance@pharmarelations.se
Website
www.pharmarelations.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.588 | 5.138 | 11.821 | 14.606 | 20.105 | 23.600 | 23.252 | 22.361 |
| Staff expenses | -4.138 | -4.433 | -8.524 | -12.545 | -16.736 | -22.634 | -22.219 | -22.013 |
| EBITDA | -15 | 705 | 665 | 2.060 | 3.370 | 966 | 1.033 | 348 |
| Depreciation & amort. | -71 | -71 | -71 | -71 | -71 | -71 | -71 | -0 |
| EBIT | -86 | 634 | 593 | 1.989 | 3.298 | 894 | 961 | 348 |
| Net financials | -1 | -7 | -13 | -50 | -24 | -29 | -65 | -22 |
| Profit before tax | -87 | 627 | 581 | 1.939 | 3.274 | 866 | 897 | 326 |
| Tax | -19 | 139 | 151 | 445 | 720 | 191 | 197 | 73 |
| Net profit | -68 | 488 | 430 | 1.494 | 2.554 | 675 | 699 | 254 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 2.385 | 3.617 | 4.999 | 8.326 | 9.055 | 8.587 | 9.990 | 11.791 |
| Equity | -18 | 470 | 900 | 2.394 | 4.948 | 5.622 | 6.322 | 6.575 |
| Long-term debt | 0 | 1.894 | 1.589 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.403 | 1.253 | 2.510 | 5.932 | 4.107 | 2.964 | 3.668 | 5.215 |
| Total debt | 2.403 | 3.147 | 4.099 | 5.932 | 4.107 | 2.964 | 3.668 | 5.215 |
EBITDA margin
1.6%
This company
15.8%
Market median
-90% vs market
20172024
Equity ratio
55.8%
This company
38.2%
Market median
+46% vs market
20172024
Return on equity
3.9%
This company
18.4%
Market median
-79% vs market
20172024
Net profit margin
1.1%
This company
8.1%
Market median
-86% vs market
20172024
Asset turnover
1.90×
This company
1.12×
Market median
+70% vs market
20172024
Debt / equity
0.79×
This company
0.62×
Market median
+27% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-11-22 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FG Management | Management | 2016 | — | — |
FA Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
PA Founder | Founder | 2016 | — | — |
ÅU Management | Management | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 90.0% | 90.0% | 2016 | |
| Individual | 90.0% | 90.0% | 2016 | |
| Individual | 5.0% | 5.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharmaRelations ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Gunnar Åke Anjou | Management | 0 companies |
| Fredrik Anjou | Chief Executive Officer | 0 companies |
| PharmaRelations AB | Founder | 0 companies |
| Åsa Uppströmer | Management | 0 companies |
| Lena Birgitta Andersson Hofsberger | Board of Directors | 0 companies |